Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.

Item

http://www.wikidata.org/entity/Q38188598

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Predictive biomarker candidate ...... targeted and cytotoxic agents.

@en

type

Item

label

Predictive biomarker candidate ...... targeted and cytotoxic agents.

@en

prefLabel

Predictive biomarker candidate ...... targeted and cytotoxic agents.

@en

P1476

Predictive biomarker candidate ...... targeted and cytotoxic agents.

@en

P2093

Hark Kyun Kim

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Green

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenic ERBB3 mutations in human cancers

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

P304

375-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.13.250

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24533716

http://www.w3.org/2001/XMLSchema#string

P921

biomarker